Retrospective Analysis of the Impact of Adalimumab Initiation on Corticosteroid Utilization and Medical Costs Among Biologic-Naïve Patients with Rheumatoid Arthritis

Medicine & Life Sciences

• Adalimumab 100%
• Biological Products 77%
• Rheumatoid Arthritis 65%
• Adrenal Cortex Hormones 63%
• Steroids 59%
• Costs and Cost Analysis 49%
• Injections 20%
• Confidence Intervals 15%
• Drug Utilization 12%
• Linear Models 6%
• Multivariate Analysis 6%
• Health Care Outcome Assessment 5%
• Logistic Models 5%
• Demography 5%
• Odds Ratio 5%
• Guidelines 5%
• Prospective Studies 5%
• Databases 5%
• Therapeutics 4%
• Health 4%